QUICK FACTS – Biomea Overview

Our Company

We are a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases and also genetically defined cancers. A covalent small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers several potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System discovery platform to advance a pipeline of novel covalent small molecule product candidates.

Our lead product candidate, BMF-219, is designed to be an oral, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in regulating the growth of beta cells in the pancreas as well as in oncogenic signaling in multiple cancers. In preclinical studies, the administration of BMF-219 produced a pronounced effect in preclinical models of diabetes by normalizing glucose levels during treatment and even after cessation of drug administration. The administration of BMF-219 has also resulted in robust anti-tumor responses across a range of liquid and solid tumor models and has been generally well-tolerated in animal studies. Today, BMF-219 is being evaluated in type 1 and type 2 diabetes and in several specific liquid and solid tumor subtypes across several ongoing clinical trials.

Beyond BMF-219, we are utilizing our novel FUSION™ System to pioneer covalent treatments against other high-value genetic drivers of disease. We entered the clinic with our second development candidate – BMF-500, a covalent inhibitor of FLT3, and are studying its use as a treatment in acute leukemia patients. Both molecules, BMF-219 and BMF-500, were developed in-house by the Biomea team.

We are currently advancing additional preclinical covalent small molecule programs for the treatment of select cancers and expect to nominate our third development candidate soon. Our goal is to utilize our capabilities and advanced platform to become a leader in developing covalent small molecules, and to uniquely maximize the depth and durability of clinical benefit when treating various cancers and metabolic conditions.

Our Management Team

After working closely together at Pharmacyclics, our Chief Executive Officer and Chairman of the Board of Directors, Thomas Butler, and Chief Operating Officer and President, Ramses Erdtmann, founded Biomea Fusion in 2017 with the shared vision and goal of developing targeted therapies for patients suffering from genetically defined cancers and metabolic diseases. Today, Biomea has grown to over 100 employees, and has built a management team with significant experience both in precision medicine and in progressing products from early-stage research to clinical trials and ultimately to regulatory approval and commercialization. Biomea has cultivated in-house expertise in medicinal chemistry, biology, translational medicine, computational biology, and chemistry, *in vitro* and *in vivo* pharmacology, biomarker development, and manufacturing. We have also established internal expertise and synergies in clinical development, clinical operations, pharmacovigilance, clinical pharmacology, regulatory affairs, and quality control. Members of the management team have held various positions at several renown biotech companies including, Gilead, and Genentech, Pharmacyclics, AbbVie, Celera, and others, and includes the co-inventors of covalent inhibitors Imbruvica, Remdesivir, and Harvoni. We are supported by our board of directors, scientific advisory board, and a leading syndicate of investors.